About TripppleHelix
Who are we?
TripppleHelix is a leading international biotech company with a global reputation for innovation and excellence. We are devoted to pushing the boundaries of science and bring the latest medical science to those who most need it around the world
TripppleHelix Knowledge
Below you will find the latest TripppleHelix educational opportunities
Gene Therapy Essentials
Design of AAV for gene therapy provides an overview of gene therapy technology in 2025. Available on Amazon.com
Stronger, faster, smarter.....
Today what can trippplehelix science accomplish? Available on Amazon.com
Dublin Longevity Summit
Come see Dr Patrick E Sewell MD lecture on the latest on gene therapy and longevity medicine in Dublin Ireland July 2-4, 2025.
Cannes France Longevity Conference
Come see Dr Patrick E. Sewell MD lecture on the latest on gene therapy and longevity medicine in Cannes France June 25 - 26, 2025.
The Gene Therapy Revolution
See Dr Patrick E. Sewell MD lecture at at Oxford University, United Kingdom
https://www.youtube.com/watch?v=0zWgyg28VLE
Comprehensive Cancer Therapy
See Dr Patrick E. Sewell MD lecture on the latest in Cancer therapy
https://www.youtube.com/watch?v=VNWV5BRQs6A
Dementia Gene Therapy
See Dr Patrick E. Sewell MD discuss Dementia Gene Therapy
Minimally Invasive Cancer Therapy
See Dr Patrick E. Sewell MD discuss his own cancer treatment. Ironically a procedure and technology he invented 26 years ago, minimally invasive renal cell carcinoma ablation, saved his life in 2023
Klotho Therapy and Lionheart
See the opening of our Lionheart anti-aging klotho therapy center, where Dr Patrick E Sewell MD provides antiaging gene therapies
The Worlds most advanced Gene Therapy Platform
Gene Addition
Gene Up Regulation
Gene Down Regulation
Gene Silencing
TRIPPLEHELIX DIVISIONS
TripppleHelix Gene Therapies
We address inherited genetic diseases as well as Healthspan and Lifespan with gene therapy
TripppleHelix Oncology
With 27 years in Oncology, we have much to offer including the only Oncologic Gene Therapy Program
TrippleHelix Cell Therapies
We have 16 years of stem cell therapy experience. We offer Mesenchymal Stem Cells and MUSE Stem Cells.
TRIPPPLEHELIX GENE THERAPIES
Gene Therapy Starts With Analysis
The worlds most extensive whole body analysis for illness and longevity
- Comprehensive tests analyzing over 850,000 CpG loci
- Epigenetic Biological Age (whole-body summary)
- Telomere Length Analysis
- Dunedin PACE (current rate of aging measurement)
- OMICm Age (developed with Harvard University)
- Extrinsic Epigenetic Age (immune system impact)
- Intrinsic Epigenetic Age (aging independent of immune system)
- Immune cell-type ratios
- CD4:CD8 ratio measurements
- Rare Disease Screening (15,000+ Conditions + EDS)
- Carrier Screening
- Cancer Risk
- Autoimmune Disorders
- Digestive Disorders & Gut Health
- Cardiovascular Health
- Brain Health
- Neurological Health
- Endocrine Health
- Medication & Drug Response
- Connective Tissue Disorders
- Musculoskeletal Health
- Respiratory Health
- Reproductive & Hormonal Health
- Skin Health
- Immune System Health
- Growth & Bone Health
- Nutritional & Metabolic Health
- Whole genomic sequencing
- Whole exon sequencing
Complete Body Systems Analysis
- Cardiovascular System
- Digestive System
- Integumentary System
- Endocrine System
- Immune System
- Lymphatic System
- Musculoskeletal System
- Neurological System
- Respiratory System
- Reproductive System
- Sensory System
- Urinary System
TRIPPPLEHELIX DISEASE GENE THERAPIES
Diseases We Can Help
- Alazami Syndrome
- ALS
- Alzheimers Disease
- Adrenomyeloneuropathy (AMN)
- Angelmans Syndrome
- Asthma
- Autism
- Becker Muscular Dystrophy
- Beta Thalasemia
- Coronary Artery Disease
- Cardiomyopathy
- CHF
- Age Related Cognitive Decline
- COPD
- Chronic Renal Insufficiency
- Danon Disease
- Duchenne’s Muscular Dystrophy
- Facioscapulohumeral Disease FSHD
- Frontotemporal Dementia
- Fibromyalgia
- Functional Neurologic Disorder
- Friedrichs Ataxia
- Frontotemporal Dementia
- HFpEF
- Hyperlipidemia
- Hypertension
- Inclusion Body Myositis
- Interstitial/Idiopathic Pulmonary Fibroses
- Juvenile Inflammatory Arthritis
- Lipoprotein A
- Medium-chain acyl-CoA dehydrogenase (MCAD) or MCAAD
- Metabolic Syndrome
- Multi-Infarct Dementia
- Myotonic Dystrophy Type II
- NAFLD
- NASH
- Non-Cystic Fibrosis Bronchiectasis NCFB
- Neuropathic Pain Syndrome
- Obesity
- Osteoarthritis
- Parkinson’s disease
- Peripheral Vascular Disease
- Pantothenate kinase-associated neurodegeneration - PKAN
- Pompe Disease
- Prader-Willi Syndrome
- Pre-Diabetes
- Protein S Deficiency
- Pulmonary Fibrosis
- Sarcopenia of Chronic Disease
- Scleroderma
- Systemic Lupus Erythematosus SLE
- SPAST - SPG4 Deficiency - Hereditary Spastic Paraplegia Type 4
- Spinal Muscular Atrophy
- Stargardt Disease
- Stroke
- Type II Diabetes
- Thymic Involution/Atrophy
- Vascular Dementia
- Visceral White Fat Burden
- White Matter Disease
- And more
TRIPPPLEHELIX LONGEVITY
LONGEVITY GENE THERAPIES
- hTERT
- Follistatin
- FGF21
- Klotho Alpha
- SIRT1
- PGC1A
- FOXO3
- VEGF
- And more
TRIPPPLEHELIX ONCOLOGY
Oncologic Analysis
Our Cancer diagnostics include:
- Cancer staging
- Cancer screening
- CT
- MRI
- PET
- Mammography
- Ultrasound
Cancer Genomic Analysis
- Next generation sequencing (NGS)
- Tumor DNA analysis
- Blood test screening
- Biopsy services
- Cancer phenotyping
- Cancer sensitivity testing
- Cancer RNA Analysis
Our cancer Therapies include the following:
- Image guided microwave ablation
- Image guided cryoablation
- Image Guided Electroporesis
- Chemoembolization
- Intratumoral Immunotherapy
- Intratumoral Chemotherapy
- IV Immunotherapy
- Anti-Cancer gene therapy
Oncologic Diseases
We custom build Precision Oncology Therapies. We provide a comprehensive oncologic analysis and therapy plan utilizing tumor ablation, immunotherapy, gene therapy for gene up regulation, gene therapy to reinstall tumor suppressors such as P53, PTEN, RB1 etc, and siRNA for gene silencing. We address the following cancers.
- Breast Cancer
- Colon Cancer
- Non-Small Cell Lung Cancer
- Other lung Cancer
- Pancreatic Cancer
- Prostate Cancer
- Melanoma
- Hepatocellular Cancer
- Other Hepatic Tumors
- Ovarian Cancer
- Glioblastoma
- Glioma
- Non Seminomatous Germ Cell Cancer
- Oral Squamous Cell Carcinoma
- Spinal Cord Tumors
- Renal Cell Carcinoma
- Sarcoma
- Neuroendocrine Tumor
- And Others
TRIPPPLEHELIX CELL THERAPIES
Tissue Regenerative Therapies
- Hair Regeneration
- ACL/PCL tear
- Rotator Cuff Tear
- Hip Arthrosis/AVN/Labral Tear/Chondromalacia
- Shoulder Arthrosis/AVN/Labral Tear/Chondromalacia/Frozen Capsul
- Arthritis Pain
- Knee Chondromalacia
- Epicondylitis
- Cutaneous Scar Removal
- Biceps Tendon tear
- Bursitis
- Fasciitis
- Meniscal Tear
- Muscle Tear
- Nerve Injury
- Neuropathic Pain
- And more
Disease Regenerative Therapies
- ALS
- Alzheimers Disease
- Stroke
- Dementia
- Discogenic Pain
- Lyme Disease
- Complex Regional Pain Syndrome/Reflex Sympathetic Dystrophy
- Seizure
- Bells Palsy
- Multiple Sclerosis
- Parkinson’s Disease
- Ovarian
- Osteomyelitis
- Non-Healing Wounds
- Occipital Pain Syndrome
- Cutaneous Fistula
- BPH
- Spinal Facet Disease
- Ischemic Wound Healing
- Hepatic Insufficiency
- Renal Insufficiency
- Peripheral Neuropathy
- And more
TripppleHelix Technology
Our Staff
Dr Patrick E Sewell MD
Founder and Chief Scientist
Dr Oliver Zolman MD
Director Longevity Science
Dr Walter Chiara MD
Medical Director – TripppleHelix Belgrade
Dr Joe Cleaver MD
Director Klotho Longevity Science
Dr. Oscar Guadarrama DVM
Director Veterinary Research and Therapy
Hashim Riaz
Chief Operating Officer
Dr Patrick E Sewell MD
Chief Scientist and Founder
Interventional Oncologist | Diagnostic Radiology | Neurointerventional, Vascular, and Body InterventionalRadiology |Stem cell Scientist \ Gene Therapist | Research Leader
Dr. Patrick E. Sewell, Jr. is a trailblazing Interventional Oncologist and visionary Chief Scientist recognized for founding the field of Interventional Oncology in 1998. With over three decades of pioneering work, Dr. Sewell has been at the forefront of advancing cancer treatment through innovative stem cell and gene therapy practices, both nationally and internationally.
Innovative Contributions in Stem Cell and Gene Therapy:
Dr. Sewell has significantly advanced the application of stem cell therapy in oncology, developing cutting-edge treatments that harness the regenerative potential of mesenchymal stem cells to combat various cancers. His expertise in stem cell therapy has led to groundbreaking case studies, including the successful application of stem cell treatments for conditions such as Bell’s Palsy, demonstrating his commitment to expanding the therapeutic horizons of regenerative medicine.
In the realm of gene therapy, Dr. Sewell has established a prominent international practice focused on anti-cancer gene therapy. His work involves the development and implementation of sophisticated gene transfer techniques aimed at targeting and eliminating cancer cells with precision. Notably, Dr. Sewell has spearheaded research projects exploring the effects of systemic human hTERT AAV gene transfer therapy on telomere length and biological aging, contributing valuable insights to the field of cancer genomics and precision oncology.
Pioneering Cryo-Ablation and Radiation Reduction Technology:
In addition to his stem cell and gene therapy endeavors, Dr. Sewell is renowned for performing the world’s first Image-Guided Percutaneous Tumor Cryo-Ablation and the first Image-Guided Percutaneous Lung Tumor Ablation in 1999. His dedication to minimizing radiation exposure culminated in the development of the world’s first radiation reduction CT software in 2005, significantly lowering the risk of iatrogenic cancer and enhancing patient safety.
Leadership and Global Entrepreneurship:
Dr. Sewell's leadership roles are extensive and impactful. As Co-Founder and Chief Scientist at TriplHelix Ltd, Chief of Gene Therapy Clinical and Research Development at 199 Biotechnologies, and President and Owner of BioGene Corp and GeneQuestX Corp, he drives forward innovative projects that integrate stem cell and gene therapies into mainstream cancer treatment protocols. His entrepreneurial spirit is further exemplified through his long-standing presidency at Regenerative Methods Corp and his ownership of multiple medical centers, including Delta Radiology Bolivar Medical Center and South Sunflower Diagnostic and Interventional Radiology.
Academic and Research Excellence:
Serving as an Assistant Professor of Radiology and Surgery at The University of Mississippi Medical Center from 1998 to 2006, Dr. Sewell led several divisions, including Interventional Oncology and Endovascular Surgery. His comprehensive education from prestigious institutions including Harvard Medical School and Stanford Medical School, coupled with numerous fellowships, underpins his deep expertise in gene therapy, cancer genomics, and precision oncology.
Global Impact and Recognition:
Dr. Sewell's international interventional oncology and gene therapy practice has earned him global recognition, with numerous invited visiting professorships across continents—from Xian University Hospital in China to Yale Medical School in the United States. His contributions to anti-cancer gene therapy have been showcased at esteemed conferences worldwide, further solidifying his status as a leader in the field.
Professional Engagement and Editorial Leadership:
A member of numerous professional organizations, including the American Medical Association, Society of Interventional Radiology, and Cardiovascular and Interventional Society of Europe, Dr. Sewell also served on several advisory boards such as the NIH Advisory Committee and the NIBIB Board of Directors. His scholarly influence extends to editorial duties for leading journals like Radiology and the Journal of Vascular and Interventional Radiology, where he contributes to shaping the discourse in medical research and practice.
Publications and Research Grants:
With an extensive portfolio of published abstracts, scientific manuscripts, and research grants, Dr. Sewell's work has profoundly impacted treatments for renal tumors, lung cancer, uterine leiomyomas, and more. His research in stem cell and gene therapies continues to push the boundaries of medical science, offering new hope and improved outcomes for cancer patients worldwide.
Commitment to Advancement:
Beyond his clinical and research endeavors, Dr. Sewell is dedicated to mentoring the next generation of medical professionals and continuously seeks innovative solutions to complex medical challenges. His unwavering commitment to advancing stem cell and gene therapy practices has not only transformed Interventional Oncology but also set new standards for patient care and medical technology on a global scale.
Dr Oliver Zolman MD
Director Longevity Science
Dr Oliver Zolman MBBS BSc is a leading longevity doctor and scientist specialising in evidence-based health optimisation and rejuvenation medicine. A graduate of King’s College London, he holds a First Class Honours degree in Regenerative Medicine and completed a Visiting Fellowship in Evidence-Based Medicine at the University of Sydney.
Oliver is at the forefront of ageing research, aiming to reverse biological aging across all 81 organ types and achieve longevity escape velocity (LEV) by 2030. As the founder of 20one Consulting and a creator of Project Blueprint with entrepreneur Bryan Johnson, Dr Zolman applies cutting-edge science to create personalised, results-driven health and longevity strategies.
His work has been featured in the BBC, Bloomberg, The Times, Guardian, New York Post, Piers Morgan, GQ, Rolling Stone, The Onion, and the 2025 Netflix Documentary "Don't Die".
Dr Walter Chiara MD
Medical Director – TripppleHelix Belgrade
Walter Chiara is a highly experienced physician and surgeon with a distinguished academic and clinical background. He earned both his Medical Degree and Bachelor’s Degree in Biology from the University of Milan, followed by advanced specialization in Surgery at the University of Pavia and Clinical Nutrition at the University of Milan. He also holds a Master’s Degree in Plastic Surgery from the University of Milan.
With decades of surgical experience, Dr. Chiara has dedicated the past twenty years to pioneering work in regenerative medicine. His early clinical innovations began with fibroblast transplantation, which progressed into the use of stem cell therapies—starting with autologous applications and later advancing to allogeneic techniques.
Dr. Chiara integrates cutting-edge treatments including bioidentical hormones, therapeutic peptides, exosomes, and intravenous medicine into his practice. He currently serves as Medical Director of Bioinst in San Marino. His private practice spans Milan, San Marino, and Belgrade.
Dr. Joe Cleaver MD
Director Klotho Longevity Science
Dr. Joe Cleaver is a pioneering physician in regenerative medicine and anti-aging therapies based in Dallas, Texas. With three decades of clinical and research experience, he holds board certifications in internal medicine and longevity medicine, complemented by fellowship training in rheumatology and immunology.
At Paradigm Wellness Medical Group LLC, Dr. Cleaver delivers personalized healthcare that addresses the root causes of aging at the cellular level. His comprehensive approach integrates regenerative medicine, lifestyle interventions, and advanced diagnostics to optimize health and extend lifespan, with particular focus on telomere health, epigenetic age, senolytic therapies, stem cell health, and Klotho protein optimization.
Dr. Cleaver has developed several groundbreaking therapies, including KLOTHAMAX™, a proprietary formulation that optimizes Klotho protein levels critical for healthspan and longevity. He pioneered the 4D LYFT™ Stem Cell Facelift, an innovative non-surgical rejuvenation procedure, and established stem cell banking for longevity patients through the Cell Surgical Network™.
As an author, Dr. Cleaver's works include the Amazon bestseller "THE ANTIAGING POWER OF KLOTHO" and the co-authored "PEPTIDE HANDBOOK" with James Lavalle RPh, CCN. A respected authority in his field, he regularly speaks at national and international conferences, trains medical professionals, and conducts clinical research advancing integrative and functional healthcare.
His mission is to empower patients to take charge of their well-being through a holistic approach that combines cutting-edge biologic therapies with personalized lifestyle modifications, redefining the boundaries of medicine to help individuals live longer, healthier, and more fulfilling lives.
At Trippplehelix, Dr Cleaver Brings his Klotho knowledge and expertise as Director of Klotho Longevity Science.
Dr. Oscar Guadarrama DVM
Director Veterinary Research and Therapy
Dr. Oscar Guadarrama is a distinguished veterinarian who has dedicated his career to advancing small animal medicine and surgery. As the General Director of Intermédica Veterinaria, he has established himself as a leader in the veterinary field.
Dr. Guadarrama currently serves as the Director of Veterinary Research and Therapy at Trippplehelix, where he leads innovative research initiatives and therapeutic developments.
He is particularly noted for his groundbreaking work in veterinary regenerative medicine. Dr. Guadarrama serves as the Medical Director of MEREVET Veterinary Regenerative Medicine, where he has developed innovative protocols for the application of Growth Factors and Stem Cells in veterinary treatments.
His expertise in regenerative therapies is widely recognized, making him an active member of the Latin American Stem Cell Society (SOLCEMA) and a founding member of the International Society of Regenerative Medicine. Dr. Guadarrama has also contributed significantly to the field as a member of the Association of Ozone Professionals A.C.
One of his notable achievements includes his contribution to the development of the veterinary version of the Madrid Declaration, an important document in the field of veterinary medicine.
Dr. Guadarrama frequently shares his knowledge as a speaker on topics related to Prolotherapy, the clinical application of platelet-rich growth factors, Regenerative Medicine, and Cell Therapy in dogs and cats. His presentations have helped educate fellow veterinarians about these cutting-edge treatments and their benefits for animal patients.
Through his clinical practice, research, and educational efforts, Dr. Oscar Guadarrama continues to advance the field of veterinary medicine, particularly in regenerative therapies that improve the quality of life for companion animals.
------------------------------------------------------------------------------------------------------------------------------------------
El Dr. Oscar Guadarrama es un distinguido veterinario que ha dedicado su carrera al avance de la medicina y cirugía de pequeños animales. Como Director General de Intermédica Veterinaria, se ha consolidado como un líder en el campo veterinario.
Actualmente, el Dr. Guadarrama ocupa el cargo de Director de Investigación y Terapia Veterinaria en Trippplehelix, donde lidera iniciativas innovadoras de investigación y desarrollos terapéuticos.
Es particularmente reconocido por su trabajo pionero en medicina regenerativa veterinaria. El Dr. Guadarrama se desempeña como Director Médico de MEREVET Medicina Regenerativa Veterinaria, donde ha desarrollado protocolos innovadores para la aplicación de Factores de Crecimiento y Células Madre en tratamientos veterinarios.
Su experiencia en terapias regenerativas es ampliamente reconocida, lo que lo convierte en miembro activo de la Sociedad Latinoamericana de Células Madre (SOLCEMA) y miembro fundador de la Sociedad Internacional de Medicina Regenerativa. El Dr. Guadarrama también ha contribuido significativamente al campo como miembro de la Asociación de Profesionales del Ozono A.C.
Uno de sus logros notables incluye su contribución al desarrollo de la versión veterinaria de la Declaración de Madrid, un documento importante en el campo de la medicina veterinaria.
El Dr. Guadarrama comparte frecuentemente su conocimiento como ponente en temas relacionados con Proloterapia, la aplicación clínica de factores de crecimiento ricos en plaquetas, Medicina Regenerativa y Terapia Celular en perros y gatos. Sus presentaciones han ayudado a educar a otros veterinarios sobre estos tratamientos de vanguardia y sus beneficios para los pacientes animales.
A través de su práctica clínica, investigación y esfuerzos educativos, el Dr. Oscar Guadarrama continúa avanzando en el campo de la medicina veterinaria, particularmente en terapias regenerativas que mejoran la calidad de vida de los animales de compañía.
Hashim Riaz
Chief Operating Officer
With over a decade of experience at the intersection of patient safety, healthcare logistics, and health technology, Hashim brings a deep operational expertise to their role as Chief Operating Officer at Trippplehelix. Having worked across both National and private healthcare sectors, they have led initiatives that enhanced patient safety protocols and optimized care delivery. Their career spans managing the distribution of medicines and medical devices, ensuring regulatory compliance and supply chain efficiency across diverse markets.
Prior to joining Trippplehelix, Hashim held senior roles in health-tech ventures focused on making healthcare more affordable and accessible. Their commitment to safety, innovation and excellence in healthcare operations positions them as a key driver of Trippplehelix’s mission and growth.
Contact Trippplehelix
